Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Linagliptin

Known as: 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, Linagliptin [Chemical/Ingredient] 
A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Highly Cited
2014
Highly Cited
2014
Kidney fibrosis is the final common pathway of all progressive chronic kidney diseases, of which diabetic nephropathy is the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
OBJECTIVE Preclinical data suggest that linagliptin, a dipeptidyl peptidase-4 inhibitor, may lower urinary albumin excretion. The… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
2013
Highly Cited
2013
BACKGROUND A substantial proportion of patients with type 2 diabetes are elderly (≥65 years) but this group has been largely… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
BACKGROUND Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2012
Highly Cited
2012
BackgroundThis study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2011
Highly Cited
2011
Aim: To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin… Expand
Highly Cited
2011
Highly Cited
2011
Aim: To assess the safety and efficacy of the potent and selective dipeptidyl peptidase‐4 inhibitor linagliptin 5 mg when given… Expand
Highly Cited
2011
Highly Cited
2011
Aim: This study assessed the influence of various degrees of renal impairment on the exposure of linagliptin, a dipeptidyl… Expand
Highly Cited
2011